BMJ: ‘Adding a sulfonylurea to metformin looks safer than switching to one’

BMJ: ‘Adding a sulfonylurea to metformin looks safer than switching to one’

July 25 2018 Switching to sulfonylureas in type 2 diabetes has been linked with an increased risk...

Effect of omega-3 or other fatty acids on heart disease is negligible finds Cochrane review

Effect of omega-3 or other fatty acids on heart disease is negligible finds Cochrane review

July 19 2018 Cochrane researchers have published research indicating that omega 3 supplements...

DOACs associated with reduced risk of major bleeding compared to warfarin

DOACs associated with reduced risk of major bleeding compared to warfarin

July 11 2018 Direct oral anticoagulants (DOACs) have been associated with reduced risks of major...

Recorded penicillin allergy associated with increased risk of MRSA and C difficile

Recorded penicillin allergy associated with increased risk of MRSA and C difficile

July 3 2018 People who have a record of penicillin allergy are at an increased risk of developing...

MPS advises of need for better awareness of cauda equina red flag symptoms

MPS advises of need for better awareness of cauda equina red flag symptoms

May 9 2018 The Medical Protection Society is advising doctors of a revision to the NICE Clinical...

  • BMJ: ‘Adding a sulfonylurea to metformin looks safer than switching to one’

    BMJ: ‘Adding a sulfonylurea to metformin looks safer than switching to one’

    Wednesday, 25 July 2018 14:07
  • Effect of omega-3 or other fatty acids on heart disease is negligible finds Cochrane review

    Effect of omega-3 or other fatty acids on heart disease is negligible finds Cochrane review

    Thursday, 19 July 2018 10:36
  • DOACs associated with reduced risk of major bleeding compared to warfarin

    DOACs associated with reduced risk of major bleeding compared to warfarin

    Wednesday, 11 July 2018 13:22
  • Recorded penicillin allergy associated with increased risk of MRSA and C difficile

    Recorded penicillin allergy associated with increased risk of MRSA and C difficile

    Tuesday, 03 July 2018 16:51
  • MPS advises of need for better awareness of cauda equina red flag symptoms

    MPS advises of need for better awareness of cauda equina red flag symptoms

    Wednesday, 09 May 2018 16:01

A pregnant lady imageApril 27 2018

Women and girls of childbearing potential must no longer take valproate medicines unless the conditions of the Pregnancy Prevention Programme are being met.

In addition, “use of valproate in pregnancy is contraindicated for bipolar disorder and must only be considered for epilepsy if there is no suitable alternative treatment.”

The medicines regulator the MHRA is calling on health professionals to ensure that “all women and girls (and their parent, caregiver, or responsible person, if necessary) are fully informed of the risks and the need to avoid exposure to valproate medicines in pregnancy.”

In a Drug Safety Update published on April 24, the MHRA says that valproate should only be considered in such circumstances if other treatments are ineffective or not tolerated, as judged by an experienced specialist.

GPs are being asked to contact all female patients who may be of childbearing potential to 

  • provide the Patient Guide;
  • check they have been reviewed by a specialist in the last year; and
  • check they are on highly effective contraception.

In addition to male and/or female sterilisation, methods of contraception considered “highly effective” are long-acting reversible contraceptives (LARC) with a less than 1% failure rate: 

  • copper intrauterine device (Cu-IUD);
  • levonorgestrel intrauterine system (LNG-IUS);
  • progestogen-only implant (IMP).

“If a user-independent form is not used, two complementary forms of contraception including a barrier method should be used and regular pregnancy testing considered,” says the MHRA.

It will be sending information to health professionals regarding the Valproate Pregnancy Prevention Programme and has updated online materials to reflect the updated status around valproates. 

Computer systems suppliers have updated pharmacy IT systems to include an alert when valproates are dispensed, and GP systems are being upgraded with a search and audit function to allow GPs to identify women on valproates.

Simon Wigglesworth, deputy chief executive of the charity Epilepsy Action, said: “We welcome the revised measures which reflect the seriousness of the risks to the unborn children of women with epilepsy during pregnancy. It is vitally important that healthcare professionals ensure that all women with epilepsy taking sodium valproate are reviewed in line with the new guidelines.”

Link:
MHRA DSU on valproate           
Epilepsy Action statement        

Clinical News

July 27 2018 Adolescent boys will be offered the human papilloma virus (HPV) vaccine to protect them from cancer, the Department of Health and Social Care has announced.
July 20 2018 Doctors are being reminded to ensure that any patient or other records which may be relevant to the UK Infected Blood Inquiry are not destroyed. Earlier this month, the Inquiry’s Chair, Sir...